Does PALBOCICLIB Cause Neoplasm recurrence? 248 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 248 reports of Neoplasm recurrence have been filed in association with PALBOCICLIB (Ibrance). This represents 0.3% of all adverse event reports for PALBOCICLIB.
248
Reports of Neoplasm recurrence with PALBOCICLIB
0.3%
of all PALBOCICLIB reports
16
Deaths
29
Hospitalizations
How Dangerous Is Neoplasm recurrence From PALBOCICLIB?
Of the 248 reports, 16 (6.5%) resulted in death, 29 (11.7%) required hospitalization, and 5 (2.0%) were considered life-threatening.
Is Neoplasm recurrence Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for PALBOCICLIB. However, 248 reports have been filed with the FAERS database.
What Other Side Effects Does PALBOCICLIB Cause?
Fatigue (15,190)
White blood cell count decreased (11,273)
Neoplasm progression (10,885)
Death (8,410)
Nausea (8,189)
Neutropenia (6,423)
Alopecia (6,201)
Diarrhoea (5,635)
Asthenia (3,660)
Off label use (3,405)
What Other Drugs Cause Neoplasm recurrence?
CYCLOPHOSPHAMIDE (293)
DOXORUBICIN (240)
VINCRISTINE (239)
CYTARABINE (223)
METHOTREXATE (198)
CARBOPLATIN (170)
RITUXIMAB (163)
ETOPOSIDE (156)
PREDNISONE (144)
DEXAMETHASONE (135)
Which PALBOCICLIB Alternatives Have Lower Neoplasm recurrence Risk?
PALBOCICLIB vs PALIPERIDONE
PALBOCICLIB vs PALIVIZUMAB
PALBOCICLIB vs PALONOSETRON
PALBOCICLIB vs PAMIDRONATE
PALBOCICLIB vs PAMIDRONIC ACID